Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies

NE Petty, J Thomas, S Radtke, HP Kiem - Med, 2023 - cell.com
While new immunotherapies have revolutionized the field of oncology, they have been
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by …
被引用次数：1 相关文章

Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies.

NE Petty, J Thomas, S Radtke, HP Kiem - Med (New York, NY), 2023 - europepmc.org
While new immunotherapies have revolutionized the field of oncology, they have been
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by …

Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies

NE Petty, J Thomas, S Radtke… - Med (New York …, 2023 - pubmed.ncbi.nlm.nih.gov
While new immunotherapies have revolutionized the field of oncology, they have been
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by …

Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies

NE Petty, J Thomas, S Radtke, HP Kiem - Med, 2023 - Elsevier
While new immunotherapies have revolutionized the field of oncology, they have been
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by …